Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Prediction of Hepatocellular Carcinoma Response to Transarterial Chemoembolization With Intravoxel Incoherent Motion Diffusion-Weighted Imaging Publisher



Ghadery AH1 ; Yazdi NA2 ; Bagheri H3 ; Kazerooni AF4, 5 ; Salahshour F2 ; Javidi SS4, 5 ; Saeedi S6 ; Rad HS4, 5 ; Shekarchi B1
Authors

Source: Egyptian Journal of Radiology and Nuclear Medicine Published:2022


Abstract

Background: There are several therapeutic options for hepatocellular carcinoma (HCC). As predicting the treatment response is critical in clinical decision making, we aimed to evaluate the quantitative intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) parameters as potential predictors of treatment response of HCC lesions to transarterial chemoembolization (TACE). Results: Twelve patients (eight males; mean age, 56.12 ± 7.88) with 26 confirmed HCC lesions were recruited in the study. Thirteen lesions (50%) responded to TACE, and the remaining lesions were categorized as nonresponder. Age > 60 year (p value: 0.018), D (p value: 0.005), D* (p value: 0.005), and f (p value: 0.004) values were significantly different in response and nonresponse group lesions. Logistic multivariate analysis showed that f value (OR: 0.847 (95% CI 0.732–0.98), p value = 0.025) could independently predict tumor response to TACE. The ROC curve analysis showed f value could predict the HCC response to TACE with sensitivity and specificity of 76.9% and 76.9%, respectively. Conclusions: IVIM-DWI parameters, especially the f value, might be useful for predicting the response of the intermediate-stage HCC to TACE. © 2022, The Author(s).
Other Related Docs
6. Brain Diffusion Mri Biomarkers After Oncology Treatments, Reports of Practical Oncology and Radiotherapy (2023)
10. Differential Diagnosis of Liver Metastases and Hemangiomas Through Diffusion Weighted Mr Imaging, Journal of Knowledge and Health in Basic Medical Sciences (2023)